
## Anilkumar Pillai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2811256/publications.pdf Version: 2024-02-01



ΔΝΗ ΚΗΜΛΟ ΡΗΤΛΙ

#	Article	IF	CITATIONS
1	C1q deletion exacerbates stress-induced learned helplessness behavior and induces neuroinflammation in mice. Translational Psychiatry, 2022, 12, 50.	4.8	3
2	Blood-brain barrier dysfunction in bipolar disorder: Molecular mechanisms and clinical implications. Brain, Behavior, & Immunity - Health, 2022, 21, 100441.	2.5	7
3	A Meta-Analysis of Brain-Derived Neurotrophic Factor Effects on Brain Volume in Schizophrenia: Genotype and Serum Levels. Neuropsychobiology, 2021, 80, 411-424.	1.9	10
4	Type 1 interferon mediates chronic stress-induced neuroinflammation and behavioral deficits via complement component 3-dependent pathway. Molecular Psychiatry, 2021, 26, 3043-3059.	7.9	21
5	Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression. Journal of Affective Disorders, 2021, 286, 275-281.	4.1	9
6	A randomized controlled trial of exercise on augmenting the effects of cognitive remediation in persons with severe mental illness. Journal of Psychiatric Research, 2021, 139, 38-46.	3.1	9
7	Mitophagy in depression: Pathophysiology and treatment targets. Mitochondrion, 2021, 61, 1-10.	3.4	23
8	Oral quetiapine treatment results in time-dependent alterations of recognition memory and brain-derived neurotrophic factor-related signaling molecules in the hippocampus of rats. Pharmacology Biochemistry and Behavior, 2020, 197, 172999.	2.9	3
9	Inflammatory Pathways in Psychiatric Disorders: the Case of Schizophrenia and Depression. Current Behavioral Neuroscience Reports, 2020, 7, 128-138.	1.3	22
10	Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement. Psychiatry Research, 2020, 291, 113285.	3.3	9
11	Chronic oral treatment with risperidone impairs recognition memory and alters brain-derived neurotrophic factor and related signaling molecules in rats. Pharmacology Biochemistry and Behavior, 2020, 189, 172853.	2.9	9
12	T115. TARGETING NICOTINIC AND NMDA RECEPTORS CONCURRENTLY: ROCKET SCIENCE, COMMON SENSE OR GAME CHANGER?. Schizophrenia Bulletin, 2019, 45, S248-S248.	4.3	1
13	Bedtime doses of prazosin do not affect daytime salivary amylase markers in PTSD. Heliyon, 2019, 5, e01709.	3.2	1
14	Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia. Current Behavioral Neuroscience Reports, 2019, 6, 37-50.	1.3	15
15	Complement component 3 levels in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder. Biomarkers in Neuropsychiatry, 2019, 1, 100007.	1.0	10
16	Complement component 3a receptor deficiency attenuates chronic stress-induced monocyte infiltration and depressive-like behavior. Brain, Behavior, and Immunity, 2018, 70, 246-256.	4.1	62
17	Estrogen Receptor β Agonist Attenuates Endoplasmic Reticulum Stress-Induced Changes in Social Behavior and Brain Connectivity in Mice. Molecular Neurobiology, 2018, 55, 7606-7618.	4.0	12
18	Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?. Schizophrenia Research, 2018, 193, 263-268.	2.0	18

ANILKUMAR PILLAI

#	Article	IF	CITATIONS
19	Transglutaminase 2 Induces Deficits in Social Behavior in Mice. Neural Plasticity, 2018, 2018, 1-9.	2.2	2
20	Neogenin in Amygdala for Neuronal Activity and Information Processing. Journal of Neuroscience, 2018, 38, 9600-9613.	3.6	21
21	Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity. Journal of Geriatric Care and Research, 2018, 5, 57-67.	1.0	4
22	Complement C3 Expression Is Decreased in Autism Spectrum Disorder Subjects and Contributes to Behavioral Deficits in Rodents. Molecular Neuropsychiatry, 2017, 3, 19-27.	2.9	42
23	Altered Expression of Endoplasmic Reticulum Stress-Related Genes in the Middle Frontal Cortex of Subjects with Autism Spectrum Disorder. Molecular Neuropsychiatry, 2017, 3, 85-91.	2.9	30
24	Estrogen Signaling as a Therapeutic Target in Neurodevelopmental Disorders. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 48-58.	2.5	57
25	The Neurobiological Basis for Social Affiliation in Autism Spectrum Disorder and Schizophrenia. Current Behavioral Neuroscience Reports, 2016, 3, 154-164.	1.3	1
26	Plasma BDNF levels following weight recovery in anorexia nervosa. Physiology and Behavior, 2016, 165, 300-303.	2.1	12
27	Long-Term Effects of Prenatal Hypoxia on Schizophrenia-Like Phenotype in Heterozygous Reeler Mice. Molecular Neurobiology, 2016, 53, 3267-3276.	4.0	17
28	Altered mRNA Levels of Glucocorticoid Receptor, Mineralocorticoid Receptor, and Co-Chaperones (FKBP5 and PTGES3) in the Middle Frontal Gyrus of Autism Spectrum Disorder Subjects. Molecular Neurobiology, 2016, 53, 2090-2099.	4.0	42
29	Glucocorticoid regulates TrkB protein levels via c-Cbl dependent ubiquitination: A decrease in c-Cbl mRNA in the prefrontal cortex of suicide subjects. Psychoneuroendocrinology, 2014, 45, 108-118.	2.7	21
30	Cysteamine, a pro-BDNF drug, as an adjunctive treatment for schizophrenia. Schizophrenia Research, 2014, 158, 268-269.	2.0	3
31	Ubiquitin-proteasome dependent degradation of GABAAα1 in autism spectrum disorder. Molecular Autism, 2014, 5, 45.	4.9	42
32	Dysregulation of estrogen receptor beta (ERβ), aromatase (CYP19A1), and ER co-activators in the middle frontal gyrus of autism spectrum disorder subjects. Molecular Autism, 2014, 5, 46.	4.9	90
33	Effects of prenatal hypoxia on schizophrenia-related phenotypes in heterozygous reeler mice: A gene×environment interaction study. European Neuropsychopharmacology, 2014, 24, 1324-1336.	0.7	30
34	Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Schizophrenia Research, 2014, 157, 84-89.	2.0	50
35	Glucocorticoid Regulates Parkin Expression in Mouse Frontal Cortex: Implications in Schizophrenia. Current Neuropharmacology, 2014, 12, 100-107.	2.9	13
36	Reliable Biomarkers and Predictors of Schizophrenia and its Treatment. Psychiatric Clinics of North America, 2012, 35, 645-659.	1.3	29

ANILKUMAR PILLAI

#	Article	IF	CITATIONS
37	Plasma BDNF Levels Vary in Relation to Body Weight in Females. PLoS ONE, 2012, 7, e39358.	2.5	76
38	Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. International Journal of Neuropsychopharmacology, 2010, 13, 535.	2.1	232
39	Cystamine prevents haloperidolâ€induced decrease of BDNF/TrkB signaling in mouse frontal cortex. Journal of Neurochemistry, 2008, 107, 941-951.	3.9	31
40	Brain-Derived Neurotropic Factor/TrkB Signaling in the Pathogenesis and Novel Pharmacotherapy of Schizophrenia. NeuroSignals, 2008, 16, 183-193.	0.9	113
41	Erythropoietin Prevents Haloperidol Treatment-Induced Neuronal Apoptosis through Regulation of BDNF. Neuropsychopharmacology, 2008, 33, 1942-1951.	5.4	41
42	Decreased Expression of Sprouty2 in the Dorsolateral Prefrontal Cortex in Schizophrenia and Bipolar Disorder: A Correlation with BDNF Expression. PLoS ONE, 2008, 3, e1784.	2.5	27
43	Long-term antipsychotic treatments and crossover studies in rats: Differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. Journal of Psychiatric Research, 2007, 41, 372-386.	3.1	128
44	Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophrenia Research, 2006, 82, 95-106.	2.0	121
45	Differential effects of haloperidol and olanzapine on levels of vascular endothelial growth factor and angiogenesis in rat hippocampus. Schizophrenia Research, 2006, 87, 48-59.	2.0	35
46	Differential effects of haloperidol and olanzapine on the expression of erythropoietin and its receptor in rat hippocampus and striatum. Journal of Neurochemistry, 2006, 98, 1411-1422.	3.9	13